Australian scientists are targeting 2036 for a live Tasmanian tiger, aligning the goal with the 100th anniversary of the last known thylacine’s death on 7 September 1936 in Hobart Zoo; the SBS article says Professor Andrew Pask is “very hopeful” a live thylacine can walk the Earth again by then, using surrogate dunnarts. The broader project is being driven through advanced gene-editing methods and a partnership with Colossal Biosciences, with earlier reporting describing a de-extinction effort backed by substantial funding and a multi-year development timeline.
For the Ark, the technical value is not the animal itself but the stack: high-fidelity genome reconstruction, targeted gene editing, marsupial surrogate breeding, and long-horizon developmental biology. These capabilities map directly onto lunar biopreservation, offline genome archives, and future rescue of extinct or collapse-threatened species, but they also expose failure points in embryo development, surrogate availability, and the need for stable cryogenic and molecular infrastructure over decades.
The Ark should monitor three things: progress in marsupial-assisted gestation, genome completeness claims versus verified functional recovery, and the regulatory or ethical barriers that will shape any future restoration program. Integrate the methods into terrestrial biodiversity contingency planning, but treat de-extinction as a proof-of-platform only if it demonstrably produces viable, healthy offspring and not just edited cells or partial embryos.